Results 161 to 170 of about 29,567 (180)

Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories

Leukemia, 2007
Charlotte Guldborg Nyvold, Giuseppe Saglio, Philipp Erben   +2 more
exaly  

Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins

Oncogene, 1999
Ruibao Ren, Paris Skourides, Ren Ruibao   +2 more
exaly  

Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine

European Journal of Medicinal Chemistry, 2015
Ya-Lin Dong, Jinyun Dong
exaly  

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

British Journal of Cancer, 2006
Ellen Weisberg, Ray A, P Manley
exaly  

BCR/ABL Oncogene

2013
M. Madden Felicella, K.-Y. Jen
openaire   +1 more source

Mechanisms of resistance to BCR–ABL TKIs and the therapeutic strategies: A review

Critical Reviews in Oncology/Hematology, 2015
Liwu Fu
exaly  

The SH3 Domain Contributes to BCR/ABL-Dependent Leukemogenesis In Vivo: Role in Adhesion, Invasion, and Homing

Blood, 1998
Calabretta Bruno, Skorski Tomasz, Trotta Rossana   +2 more
exaly  

BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients

Leukemia, 2010
Carlo Gambacorti Passerini, Sara Redaelli, E M Pogliani   +2 more
exaly  

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Blood, 2007
Arghya Ray, Ray Arghya, Mestan Jürgen   +2 more
exaly  

ABL-BCR expression in BCR-ABL-positive human leukemia cell lines

Leukemia Research, 1999
Cord Uphoff, Yoshinobu Matsuo, H G Drexler   +2 more
exaly